Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25N |
| Molecular Weight | 279.4192 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=CFOOTBBXHJHHMT-UHFFFAOYSA-N
InChI=1S/C20H25N/c1-17(2)21-15-13-20(14-16-21,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3-12,17H,13-16H2,1-2H3
| Molecular Formula | C20H25N |
| Molecular Weight | 279.4192 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Prodipine (also known as BY-101) is diphenylpiperidines derivative patented by Chemische Fabrik Promonta G.m.b.H. as an anti parkinsonian agent. Prodipine showed monoamine oxidase inhibiting effects in vitro (liver and brain homogenates) similar to those of harmaline. In preclinical studies, Prodipine caused no tachyphylaxis, no increased salivation, or hyperthermia, and had lower toxicity in mice than amphetamine or pemoline. Prodipine decreased reserpine-induced ptosis, antagonized tremorine-induced seizures, and caused only mild hypertension in mice.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/347467
20 mg
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:56 GMT 2025
by
admin
on
Mon Mar 31 18:27:56 GMT 2025
|
| Record UNII |
51567MYG7V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C38149
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65775
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
C016695
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
C73306
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
DTXSID20185247
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
51567MYG7V
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
31314-38-2
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
100000081118
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
SUB10068MIG
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
3358
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | |||
|
m1237
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL277382
Created by
admin on Mon Mar 31 18:27:56 GMT 2025 , Edited by admin on Mon Mar 31 18:27:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |